Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511706 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT00511706 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 243 participants.
The verdict
NCT00511706, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Interventions
- DRUG dexamethasone
- BIOLOGICAL ranibizumab
- OTHER sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2007-11-01 |
| Est. Completion | 2009-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511706
The ClinicalTrials.gov registry entry for NCT00511706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00511706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511706 about?
NCT00511706 is a clinical study titled "Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)". The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
What is the current status of trial NCT00511706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2007-11-01. Estimated completion is 2009-03-01.
What interventions are being tested in trial NCT00511706?
The interventions under investigation include: dexamethasone (DRUG), ranibizumab (BIOLOGICAL), sham (OTHER).
Who is sponsoring clinical trial NCT00511706?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.